Viking Therapeutics is a biotechnology company focused on developing potential treatments for metabolic and endocrine disorders.
Its activities centre on research and clinical development, including programmes associated with obesity and liver disease. Clinical evidence is central to progressing experimental medicines.
Developing new medicines requires clinical studies to evaluate safety and effectiveness before potential regulatory approval. Research outcomes, development funding and trial progress shape a biotechnology company's path, particularly when its programmes have not yet become established commercial products.
Relacionado con Noticias e información del mercado